Exploring Intellia Therapeutics, Inc. (NTLA) Investor Profile: Who’s Buying and Why?

Are you keeping a close watch on Intellia Therapeutics, Inc. (NTLA) and wondering about the bigger picture behind the stock movements? As of April 17, 2025, the share price stands at $7.23, a significant 66.48% decrease from $21.57 on April 19, 2024. With 567 institutional owners holding a total of 124,223,851 shares, who are the major players influencing NTLA's trajectory, and what are their strategies? Are these shifts driven by long-term confidence in Intellia's CRISPR-based therapies, or are short-term market dynamics at play? Dive in to uncover the key investors, their recent activities, and the factors driving their investment decisions.

Intellia Therapeutics, Inc. (NTLA) Who Invests in Intellia Therapeutics, Inc. (NTLA) and Why?

Understanding the investor profile of Intellia Therapeutics, Inc. (NTLA) involves examining the various types of investors, their motivations, and the strategies they employ. This insight is crucial for current and potential investors, as it sheds light on the overall market sentiment and the factors driving investment decisions regarding Intellia Therapeutics, Inc. (NTLA).

Key Investor Types: Intellia Therapeutics, Inc. (NTLA) attracts a diverse range of investors, each with their own investment horizons and risk tolerances.

• Retail Investors: These individual investors may be drawn to Intellia Therapeutics, Inc. (NTLA) due to its potential for high growth in the gene editing space. They often invest based on the company's innovative technology and long-term prospects.
• Institutional Investors: This category includes mutual funds, pension funds, and insurance companies. These investors typically have a longer investment horizon and conduct thorough research before investing. Their investment decisions can significantly impact Intellia Therapeutics, Inc. (NTLA)'s stock price.
• Hedge Funds: Hedge funds often employ more aggressive investment strategies, seeking short-term gains. They may invest in Intellia Therapeutics, Inc. (NTLA) based on specific catalysts, such as clinical trial results or regulatory approvals.

Investment Motivations: Several factors attract investors to Intellia Therapeutics, Inc. (NTLA):

• Growth Prospects: The gene editing industry is rapidly evolving, and Intellia Therapeutics, Inc. (NTLA) is at the forefront of this innovation. Investors are drawn to the potential for significant revenue growth as the company's therapies advance through clinical trials and gain regulatory approval.
• Market Position: As a leading company in the CRISPR-based gene editing field, Intellia Therapeutics, Inc. (NTLA) holds a strong competitive position. This market leadership attracts investors seeking exposure to cutting-edge technology and innovative therapeutic approaches.

Investment Strategies: Investors in Intellia Therapeutics, Inc. (NTLA) adopt various strategies, depending on their investment goals and risk appetite:

• Long-Term Holding: Many institutional investors and some retail investors adopt a long-term holding strategy, based on the belief that Intellia Therapeutics, Inc. (NTLA)'s gene editing technology will generate substantial returns over time. This strategy involves holding the stock for several years, weathering short-term market fluctuations.
• Short-Term Trading: Hedge funds and some retail investors may engage in short-term trading, seeking to profit from short-term price movements. This strategy is often based on technical analysis or anticipation of specific news events.

Here is a table illustrating potential investment strategies based on investor type:

Understanding these diverse investor profiles, motivations, and strategies provides a comprehensive view of the market dynamics surrounding Intellia Therapeutics, Inc. (NTLA). This knowledge is invaluable for anyone looking to make informed investment decisions about the company.

To gain further insights into the company's direction, explore Mission Statement, Vision, & Core Values of Intellia Therapeutics, Inc. (NTLA).

Intellia Therapeutics, Inc. (NTLA) Institutional Ownership and Major Shareholders of Intellia Therapeutics, Inc. (NTLA)

Institutional ownership in Intellia Therapeutics, Inc. (NTLA) reflects the confidence and strategic interest of large investment firms in the company's potential. These major shareholders can significantly influence NTLA's stock price and corporate strategy through their investment decisions and voting power.

Here's an overview of Intellia Therapeutics, Inc. (NTLA)'s institutional ownership profile:

• Top Institutional Investors: The largest institutional investors in Intellia Therapeutics, Inc. (NTLA) include entities like Vanguard Group, BlackRock Fund Advisors, and State Street Global Advisors. These firms hold substantial stakes, reflecting their belief in the long-term value of the company.
• Shareholdings: Specific shareholdings can fluctuate, but these major institutions typically maintain significant positions, often representing a substantial percentage of the company's outstanding shares. For instance, Vanguard Group might hold over 8% of the shares, while BlackRock Fund Advisors could have around 7%.

Examining recent changes in ownership provides insights into the evolving sentiment of institutional investors:

• Increased Stakes: Some institutional investors may have increased their positions in Intellia Therapeutics, Inc. (NTLA), signaling positive expectations for the company's future performance, perhaps driven by promising clinical trial results or strategic partnerships.
• Decreased Stakes: Conversely, other institutions might have reduced their holdings, potentially due to portfolio rebalancing, risk management considerations, or concerns about the company's prospects.

The moves of major institutional investors can have a pronounced impact on Intellia Therapeutics, Inc. (NTLA):

• Stock Price: Large purchases by institutional investors can drive up the stock price, while significant sales can exert downward pressure.
• Company Strategy: Institutional investors often engage with company management to influence strategic decisions, such as research and development priorities, capital allocation, and corporate governance practices.

Here’s a look at some of the top institutional holders of Intellia Therapeutics, Inc. (NTLA):

These ownership dynamics play a crucial role in shaping Intellia Therapeutics, Inc. (NTLA)'s market behavior and strategic direction. Monitoring these institutional movements is essential for understanding the company's overall investment landscape.

For more detailed information, you can explore: Intellia Therapeutics, Inc. (NTLA): History, Ownership, Mission, How It Works & Makes Money

Intellia Therapeutics, Inc. (NTLA) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Intellia Therapeutics, Inc. (NTLA) provides critical insights into the company's stability, strategic direction, and stock performance. A diverse ownership structure comprising institutional investors, retail investors, and company insiders shapes the dynamics of NTLA.

As of April 2025, 566 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 124,223,634 shares. Institutional investors hold approximately 98.21% of Intellia Therapeutics, Inc.'s shares, with a total value of holdings amounting to $735 million.

Here are some of the top institutional investors in Intellia Therapeutics, Inc. and their influence:

• ARK Investment Management LLC: Holding 12,536,386 shares, representing 12.11% ownership. ARK Investment Management increased its holdings by 2.24% in the last quarter of 2024.
• BlackRock, Inc.: With 10,857,693 shares, accounting for 10.49% ownership.
• Vanguard Group Inc.: Owning 10,190,053 shares, which is 9.84% ownership.
• ARKK - ARK Innovation ETF: Holding 8,733K shares representing 8.44% ownership. The firm increased its portfolio allocation in NTLA by 1.47%.
• State Street Corp: Holding 5,205,698 shares, representing 5.03% ownership.
• Morgan Stanley: Holding 3,814,546 shares.
• Regeneron Pharmaceuticals Inc: Holding 3,702,995 shares.
• Nikko Asset Management Americas, Inc.: Holding 2,992,663 shares. Nikko Asset Management Americas decreased its portfolio allocation in NTLA by 5.20% over the last quarter.
• Sumitomo Mitsui Trust Holdings, Inc.: Also holding 2,992,663 shares.
• VTSMX - Vanguard Total Stock Market Index Fund Investor Shares: Holding 3,042K shares representing 2.94% ownership. In its prior filing, the firm reported owning 3,175K shares , representing a decrease of 4.37%.

These major shareholders can significantly influence company decisions and stock movements. For instance, Schedule 13D filings indicate investors holding more than 5% of the company may actively pursue changes in business strategy, while Schedule 13G filings indicate passive investments exceeding 5%.

Recent moves by institutional investors reflect changing sentiments and strategic adjustments:

• Hedge funds increased their holdings by 475.7K shares last quarter.
• Total shares owned by institutions increased in the last three months by 6.41% to 124,191K shares.
• The average one-year price target for Intellia Therapeutics (NasdaqGM:NTLA) has been revised to $60.

However, there have also been some reductions in holdings, such as Nikko Asset Management Americas decreasing its position by 5.20% in the last quarter.

The ownership structure of Intellia Therapeutics, Inc. also includes:

• Insiders: Owning approximately 1.59% of the company's stock.
• Public Companies and Individual Investors: Holding around 49.60%.

Notably, Rachel E. Haurwitz is the largest individual shareholder, owning 5,593,846 shares, representing 5.40% of the company.

The fund sentiment score, which indicates the level of institutional accumulation, is a crucial metric. It uses a multi-factor quantitative model to identify companies with the highest levels of institutional accumulation, ranging from 0 to 100, with higher numbers indicating greater accumulation.

Recent news indicates some volatility and shifts in analyst sentiment:

• HC Wainwright & Co. initiated coverage of Intellia Therapeutics (NTLA) with a Buy recommendation.
• JP Morgan downgraded Intellia Therapeutics (NTLA).
• Morgan Stanley also downgraded Intellia Therapeutics (NTLA).

These ratings changes can influence investor confidence and stock performance.

Here's a summary of the key ownership information:

Overall, Intellia Therapeutics, Inc. has a strong institutional presence, which can provide stability and long-term investment. However, shifts in holdings and analyst ratings should be monitored closely for potential impacts on the company's stock.

For further insights into Intellia Therapeutics, Inc.'s financial health, you can explore: Breaking Down Intellia Therapeutics, Inc. (NTLA) Financial Health: Key Insights for Investors

The share price as of April 17, 2025 was $7.23 / share. Previously, on April 19, 2024, the share price was $21.57 / share. This represents a decline of 66.48% over that period.

Indian investors sentiment towards Intellia Therapeutics (NTLA) : Investment in Intellia Therapeutics Shares from India has grown by 48.91% over the past 30 days, indicating increased transactional activity. Search interest for Intellia Therapeutics Stock from India on INDmoney has decreased by -13% in the last 30 days, reflecting a downward trend in search activity.

In March 1, 2025, it awarded an inducement grant to eleven new employees under Intellia's 2024 Inducement Plan as a material inducement to employment. The inducement grant consisted of time-based restricted stock units (“RSUs”) for 32,600 shares of Intellia's common stock, with one-third of such RSUs vesting on March 1, 2026, 2027 and 2028.

Intellia Therapeutics, Inc. (NTLA) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to Intellia Therapeutics, Inc. (NTLA) is crucial for assessing the company's current position and future prospects. Examining the moves of major shareholders, analysts' perspectives, and overall market behavior provides a comprehensive view of investor confidence and potential impacts on the stock.

Recent market reactions to Intellia Therapeutics, Inc. (NTLA) can offer insights into how the stock performs following significant ownership changes or large investor moves. For example, positive clinical trial results often lead to increased investor confidence and a rise in stock price, while setbacks or regulatory hurdles may cause the opposite effect. Monitoring these reactions helps gauge the immediate impact of key events on the company's valuation.

Analyst perspectives play a vital role in shaping investor sentiment towards Intellia Therapeutics, Inc. (NTLA). Analysts provide insights based on their research and analysis, which can influence investor decisions. These perspectives typically cover:

• Financial Performance: Evaluation of revenue, earnings, and cash flow.
• Growth Prospects: Assessment of the company's pipeline and market opportunities.
• Risk Factors: Identification of potential challenges, such as regulatory hurdles or competition.

The collective sentiment of major shareholders significantly influences the stability and direction of Intellia Therapeutics, Inc. (NTLA). Positive sentiment from large institutional investors can attract more investment, driving up the stock price. Conversely, negative sentiment may lead to sell-offs, impacting the company's market value. Keeping track of these major players and their positions provides valuable insights into the overall investor confidence in Intellia Therapeutics, Inc. (NTLA).

Here’s a look at potential impacts related to investor activities:

• Increased Investment by Institutional Investors: Often viewed positively, signaling confidence in Intellia Therapeutics, Inc. (NTLA)’s long-term prospects.
• Decreased Investment by Institutional Investors: May raise concerns about the company's future performance.
• Analyst Upgrades: Typically lead to a short-term increase in stock price.
• Analyst Downgrades: Can result in a decline in stock price.

For additional insights into Intellia Therapeutics, Inc. (NTLA)'s strategic direction, you might find this resource helpful: Mission Statement, Vision, & Core Values of Intellia Therapeutics, Inc. (NTLA).